NASDAQ:PCRX

Pacira BioSciences (PCRX) Stock Price, News & Analysis

Pacira BioSciences logo
$36.48 0.00 (0.00%)
As of 11/19/2026

About Pacira BioSciences Stock (NASDAQ:PCRX)

Advanced

Key Stats

Today's Range
$36.48
▼
$36.48
50-Day Range
$24.08
▼
$36.49
52-Week Range
$18.80
▼
$36.67
Volume
N/A
Average Volume
1.07 million shs
Market Capitalization
$1.46 billion
P/E Ratio
39.23
Dividend Yield
N/A
Price Target
$33.33
Consensus Rating
Hold

Company Overview

Pacira BioSciences is a biopharmaceutical company focused on non-opioid approaches to pain management and related health needs. Its portfolio includes medicines and a device intended for use in surgical, musculoskeletal and other care settings.

The company’s products include EXPAREL, a long-acting bupivacaine formulation used for postsurgical pain management; ZILRETTA, an extended-release corticosteroid injection for knee osteoarthritis pain; and the iovera system, which uses targeted cold to temporarily block peripheral nerves and relieve pain.

Founded as Pacira Pharmaceuticals, the company adopted the Pacira BioSciences name in 2019. It markets products in the United States and uses commercial partners to support access in international markets.

AI Generated. May Contain Errors.

Pacira BioSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

PCRX MarketRank™: 
1.79975261132 of 5 stars

Pacira BioSciences scored higher than 36% of companies evaluated by MarketBeat, and ranked 677th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on no strong buy ratings, 1 buy rating, 10 hold ratings, and no sell ratings.

  • Downside Risk

    Pacira BioSciences has a consensus price target of $33.33, representing about 8.6% downside from its current price of $36.48.

  • Amount of Analyst Coverage

    Pacira BioSciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Pacira BioSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Pacira BioSciences are expected to grow by 23.68% in the coming year, from $1.90 to $2.35 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pacira BioSciences is 39.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.09.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pacira BioSciences is 39.23, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.07.

  • Price to Book Value per Share Ratio

    Pacira BioSciences has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.97% of the float of Pacira BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Pacira BioSciences has a short interest ratio ("days to cover") of 3.91, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pacira BioSciences has recently decreased by 21.40%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pacira BioSciences does not currently pay a dividend.

  • Dividend Growth

    Pacira BioSciences does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Pacira BioSciences this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $217,920.00 in company stock.

  • Percentage Held by Insiders

    6.40% of the stock of Pacira BioSciences is held by insiders.

  • Percentage Held by Institutions

    99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pacira BioSciences' insider trading history.
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PCRX Stock News Headlines

Viatris completes $1.6B acquisition
Pacira BioSciences, Inc. Announces Management Changes
Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
Viatris Completes Acquisition of Pacira BioSciences
Viatris Reports Third-Quarter 2026 Financial Results
See More Headlines

PCRX Stock Analysis - Frequently Asked Questions

Pacira BioSciences' stock was trading at $25.88 at the beginning of the year. Since then, PCRX shares have increased by 41.0% and is now trading at $36.48.

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its earnings results on Thursday, November, 5th. The company reported $0.70 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.75 by $0.05. The business had revenue of $176.65 million for the quarter, compared to the consensus estimate of $181.94 million. Pacira BioSciences had a trailing twelve-month return on equity of 11.91% and a net margin of 5.08%.

Pacira BioSciences (PCRX) raised $64 million in an IPO on Wednesday, February 2nd 2011. The company issued 4,250,000 shares at a price of $14.00-$16.00 per share.

Top institutional investors of Pacira BioSciences include State Street Corp (5.35%), Goldman Sachs Group Inc. (3.70%), Gagnon Securities LLC (1.57%) and Bridge City Capital LLC (0.88%). Insiders that own company stock include Jonathan Slonin, Daryl Gaugler, Frank D Lee, Shawn Cross, Kristen Williams, Lauren Riker, Mark Froimson and Marcelo Bigal.
View institutional ownership trends
.

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include Gilead Sciences (GILD), Micron Technology (MU), Tesla (TSLA), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Palo Alto Networks (PANW) and Alphabet (GOOG).

Company Calendar

Last Earnings
11/05/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PCRX
CIK
1396814
Employees
829
Year Founded
2006

Price Target and Rating

High Price Target
$36.50
Low Price Target
$25.00
Potential Upside/Downside
-8.6%
Consensus Rating
Hold
Rating Score (0-4)
2.09
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.93
Trailing P/E Ratio
39.23
Forward P/E Ratio
15.52
P/E Growth
N/A
Net Income
$7.03 million
Net Margins
5.08%
Pretax Margin
4.97%
Return on Equity
11.91%
Return on Assets
6.61%

Debt

Debt-to-Equity Ratio
0.41
Current Ratio
4.68
Quick Ratio
3.65

Sales & Book Value

Annual Sales
$743.30 million
Price / Sales
1.97
Cash Flow
$3.86 per share
Price / Cash Flow
9.46
Book Value
$17.77 per share
Price / Book
2.05

Miscellaneous

Outstanding Shares
40,095,000
Free Float
37,529,000
Market Cap
$1.46 billion
Optionable
Optionable
Beta
0.21

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:PCRX) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners